27 April 2020 

China has granted approval to assess a second coronavirus vaccine candidate against Covid-19 in the second phase of clinical trials; this is the third Covid-19 vaccine to enter clinical development. According to state-run Xinhua news agency, an inactivated vaccine created by Wuhan Institute of Biological Products under the China National Pharmaceutical Group, Sinopharm, and the Wuhan Institute of Virology (WIV) entered clinical trials.

Immunotherapies developer Scancell has launched a research programme focused on developing a DNA vaccine candidate to protect from Covid-19. The vaccine will be designed to act on the SARS-CoV-2 nucleocapsid protein and the main receptor-binding domain of the spike S protein. The project will involve researchers from the University of Nottingham, Centre for Research on Global Virus Infections, the Biodiscovery Institute and Nottingham Trent University.

The UK Government has approved a clinical trial to assess plasma therapy for the treatment of Covid-19 patients. A scaled-up national programme, if effective, will supply up to 10,000 units of convalescent plasma each week to the National Health Service (NHS), enabling treatment of 5,000 patients per week.

Serum Institute of India has plans to manufacture the Covid-19 vaccine candidate developed by the University of Oxford in the next two to three weeks, with an aim to produce five million doses per month during the initial six months and then scale-up to ten million doses per month. The company is one of the seven global organisations producing the vaccine.

Australia-based Mesoblast has reported that 83% of ventilator-dependent Covid-19 patients suffering from moderate and severe acute respiratory distress syndrome (ARD) treated with two IV infusions of its allogeneic mesenchymal stem cell candidate, remestemcel-L, showed survival in first five days of a clinical trial. All patients were treated at Mt Sinai hospital, New York, US as part of an emergency investigational new drug (IND) application or expanded access protocol.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.